Abstract
Introduction. Pulmonary embolism (PE) is a relatively common complication in COVID 19. The cornerstone of PE medical treatment is anticoagulant therapy. However, anticoagulants may cause severe bleeding. Patients with PE and hemoptysis are often very difficult to treat.
Case report. We presented a case of a young patient who developed a COVID 19 induced pneumonia. During hospital treatment, he developed PE why the dose of anticoagulants was increased. Soon after the dose was increased, the patient developed massive hemoptysis. A team of physicians decided to continue with anticoagulants and to introduce a hemostatic into the therapy. The patient responded well to the therapy and he was dismissed from the hospital after two weeks of treatment.
Conclusion. Patients with PE and hemoptysis are often difficult to treat as the treatment of PE can worsen hemoptysis. This is why the decision on the treatment should be made by a team of physicians.
Keywords
References
- Autori zadržavaju autorska prava i pružaju časopisu pravo prvog objavljivanja rada i licenciraju ga "Creative Commons Attribution licencom" koja omogućava drugima da dele rad, uz uslov navođenja autorstva i izvornog objavljivanja u ovom časopisu.
- Autori mogu izraditi zasebne, ugovorne aranžmane za neekskluzivnu distribuciju članka objavljenog u časopisu (npr. postavljanje u institucionalni repozitorijum ili objavljivanje u knjizi), uz navođenje da je članak izvorno objavljen u ovom časopisu.
- Autorima je dozvoljeno i podstiču se da postave objavljeni članak onlajn (npr. u institucionalni repozitorijum ili na svoju internet stranicu) pre ili tokom postupka prijave rukopisa, s obzirom da takav postupak može voditi produktivnoj razmeni ideja i ranijoj i većoj citiranosti objavljenog članka (Vidi Efekti otvorenog pristupa).